Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.


We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by Reaxense.


Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.


We utilise our cutting-edge, exclusive workflow to develop focused libraries.


 

Fig. 1. The screening workflow of Receptor.AI

By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.


Our library stands out due to several important features:


  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.

  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.

  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.

  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
Q96RL6

UPID:
SIG11_HUMAN

ALTERNATIVE NAMES:
-

ALTERNATIVE UPACC:
Q96RL6

BACKGROUND:
The Sialic acid-binding Ig-like lectin 11, known for mediating sialic-acid dependent cell adhesion, is pivotal in immune regulation. It preferentially binds to alpha-2,8-linked sialic acid, with its sialic acid recognition site potentially masked by cis interactions. In immune responses, Siglec-11 may inhibit signal transduction by recruiting cytoplasmic phosphatases via SH2 domains, which dephosphorylate signaling molecules.

THERAPEUTIC SIGNIFICANCE:
Exploring the functions of Sialic acid-binding Ig-like lectin 11 offers a promising avenue for developing novel therapeutic approaches. Its role in inhibiting signal transduction during immune responses positions it as a valuable target for therapeutic intervention in immune-related disorders.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.